SSY Group Limited

2005

KYG8406X1034

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
4.71 ^HKD	+0.64%		-4.66%	-4.66%

Apr. 16	SSY Group Logs Nearly 15% Boost in Q1 Profit	MT
Apr. 08	SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	MT

SSY Group Limited Announces Interim Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 30 September 2022

August 29, 2022 at 12:03 am EDT

SSY Group Limited announced interim Ordinary Dividend of HKD 0.06 per share for the six months ended 30 June 2022. Ex-dividend date is 16 September 2022. Record date is 20 September 2022.

Payment date is 30 September 2022.

Latest news about SSY Group Limited

SSY Group Logs Nearly 15% Boost in Q1 Profit	Apr. 16	MT
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	Apr. 08	MT
SSY Group Limited Announces Update on Product Development	Apr. 08	CI
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	Apr. 03	MT
SSY Group Limited Provides Update on Product Development	Apr. 03	CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
SSY Group Obtains Drug Administration Approval for Diabetes Drug	Mar. 25	MT
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	Mar. 20	MT
SSY Group Limited Announces Update on Product Development	Mar. 20	CI
SSY Group Gets Bulk Drug Approval from Chinese Authorities	Mar. 01	MT
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	Mar. 01	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	Feb. 29	CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	Feb. 29	CI
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	Feb. 27	MT
SSY Group Limited Receives Approval for Gliclazide Tablet	Feb. 27	CI
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	Feb. 23	MT
SSY Group Limited Provides Update on Product Development	Feb. 22	CI
SSY Group’s Anesthetic Drug Granted Production, Registration Approval in China	Feb. 19	MT
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China	Feb. 18	CI
SSY Group Gets Bulk Drug Approval in China	Jan. 31	MT
SSY Group Limited Announces Update on Product Development	Jan. 31	CI
SSY Obtains Chinese Bulk Drug Registration Nod for Lidocaine Hydrochloride	Jan. 23	MT
SSY Group Limited Provides Update on Product Development	Jan. 23	CI
SSY Group Limited Appoints Liu Wenjun as Non-Executive Director	Jan. 19	CI
SSY Group’s Potassium Chloride Injection Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	Jan. 18	MT

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for SSY Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.71 HKD

Average target price

6.227 HKD

Spread / Average Target

+32.20%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SSY GROUP LIMITED	-4.66%	1.77B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals